Risk of cardiovascular adverse events from trastuzumab (Herceptin(®)) in elderly persons with breast cancer: a population-based study

Por Tsai, H.-T., Isaacs, C., Fu, A. Z., Warren, J. L., Freedman, A. N., Barac, A., Huang, C.-Y., Potosky, A. L.
Publicado em 2014

Cardiometabolic Risk Factors and Survival after Breast Cancer in the Women’s Health Initiative

Por Simon, MS, Beebe Dimmer, JL, Hastert, TA, Manson, JE, Cespedes Feliciano, EM, Neuhouser, ML, Ho, GYF, Freudenheim, JL, Strickler, H, Ruterbusch, J, Barac, A, Chlebowski, R, Caan, B
Publicado no Cancer (2018)

Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study

Por Lynce, F., Barac, A., Geng, X., Dang, C., Yu, A. F., Smith, K. L., Gallagher, C., Pohlmann, P. R., Nunes, R., Herbolsheimer, P., Warren, R., Srichai, M. B., Hofmeyer, M., Cunningham, A., Timothee, P., Asch, F. M., Shajahan-Haq, A., Tan, M. T., Isaacs, C., Swain, S. M.
Publicado no Breast Cancer Res Treat (2019)